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Urinary Survivin and the Detection of Recurrent Transitional Cell Carcinoma of the 
Bladder. Justin J. Cohen, Derek A. Hausladen, Marcia A. Wheeler, Christopher J. Cutie, 
M. Grey Maher, John W. Colberg, and Robert M. Weiss. Section of Urology, 
Department of Surgery, Yale University School of Medicine, New Haven, CT. 
We investigated whether urinary survivin, an inhibitor of apoptosis protein 
expressed in many human cancers but few normal adult tissues, could be used as a non- 
invasive method of detecting recurrence of transitional cell carcinoma (TCC) of the 
bladder. Urine samples were collected from 121 patients, 98 with treated TCC in 
remission and 23 with recurrent bladder cancer, and analyzed for survivin content using a 
novel, antibody based detection system. Mean normalized survivin levels were 
significantly higher in patients with recurrent TCC than in patients with TCC in 
remission [0.54 ng/mL(±l. 17, n=23) vs. 0.07 ng/mL (±0.15, n=98), p<0.001]. Further, 
patients with invasive recurrent tumors had significantly higher survivin levels than 
patients with superficial recurrent tumors [1.35 ng/mL (±1.86, n=6) vs. 0.25 ng/mL 
(±0.67, n=17), p=0.012] and patients in remission [1.35 ng/mL (±1.86, n=6) vs. 0.07 
ng/mL (±0.15, n=98), p<0.001]. The difference between survivin values of superficial 
recurrent tumors and tumors in remission was not significant [0.25 ng/mL (±0.67, n=17) 
vs. 0.07 ng/mL (±0.15, n=98), p=0.36]. The overall sensitivity of the assay for recurrent 
bladder cancer in this series is 52.2%, and the specificity is 84.7%, at a survivin value of 
0.12 ng/mL. The sensitivity ranges from 41.2% for identifying superficial recurrence to 
83.3% for identifying invasive recurrence. Urinary survivin analysis thus appears to be a 
specific noninvasive method of monitoring for bladder tumor recurrence. 
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Cancer remains second only to cardiovascular disease as the leading cause of 
death in the United States. From 1992 through 1998, cancer death rates declined for both 
males and females, and incidence rates declined for males but increased for females. 
During this time period, overall rates, if one takes into account males and females, for 
both incidence and mortality of cancer declined by an average of 1.1 percent each year. 
However, despite these improvements, men have a 43.39 percent and women a 38.25 
percent chance of developing cancer during their lifetime (1). 
It was expected that 56,500 cases of urinary bladder cancer were to be diagnosed 
in the United States in 2002, with a male to female ratio of 2-2.5 to 1 (41,500 male cases 
and 15,000 female cases). This makes bladder cancer the fourth most common and tenth 
most common site of new cancer diagnoses in men and women, respectively, accounting 
for 7% of the newly diagnosed cancer cases in men and 2% of the newly diagnosed 
cancer cases in women. It is the second most frequent tumor of the genitourinary system. 
Bladder cancer was estimated to cause 8,600 male and 4,000 female deaths during that 
same year, making it the ninth most common cause of cancer death in men (1). 
Even though the incidence of bladder cancer and mortality due to this disease 
remain high, survival rates of those affected by it have increased significantly over the 
past 25 years. While bladder cancer patients in the United States could expect only a 
73% chance of survival at five years between 1974 and 1976, the five-year survival rates 
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increased to 78% between 1983 and 1985, and 81% between 1992 and 1997. Similar 
trends were seen both in the white (74% five-year survival between 1974 and 1976; 82% 
between 1992 through 1997) and African American (48% five-year survival between 
1974 and 1976; 65% between 1992 through 1997) populations (1). 
The majority of bladder tumors in the United States and Northern Europe are 
transitional cell carcinomas (TCC), comprising greater than 90 percent of reported cases. 
Squamous cell carcinoma, adenocarcinoma, and undifferentiated carcinoma make up the 
remainder of bladder cancers in these regions. Prevalence of TCC peaks in the sixth and 
seventh decades (2). In contrast, bladder cancer is the most common cancer in areas of 
the world with endemic schistosomaisis, such as Egypt, and the majority of these cancers 
are squamous cell carcinomas peaking in the fourth and fifth decades of life (2, 3). 
Many environmental factors have been shown to increase the risk of developing 
bladder cancer. In 1895, Rehn showed an association between dye workers who worked 
with aniline dyes and bladder cancer, making it the first cancer to be associated with 
industrialization (4). Since that time, various aromatic amines have been associated with 
an increased risk of bladder cancer, including those found in hair dyes, cigarette smoke, 
and the rubber, textile and chemical industries (4, 5). 
The most significant environmental risk factor is cigarette smoking, which is 
estimated to cause up to 65 percent of bladder cancers in males and 25 percent in females 
(6-8). Smoking increases the risk of developing bladder cancer at least three-fold, with 
those who smoke for longer periods of time at higher risk than those who smoke less. 
Aromatic amines, tobacco hydrocarbons and tar are the chemicals in cigarette smoke 
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implicated in causing the high cancer rates in smokers (5), and patients who are slow 
acetylators of aromatic amines are at an increased risk of developing bladder cancer (7). 
Other factors have been shown to increase the risk of developing bladder cancer. 
Food products such as coffee, artificial sweeteners and water contaminants are thought by 
some to be carcinogenic in the bladder. The drugs phenacetin, chlomaphazine and 
cyclophosphamide have been strongly implicated in oncogenesis. The parasite 
Schistosoma haematobium has been shown in Africa to cause squamous cell bladder 
cancers. Further, recurrent urinary tract infections and certain genetic polymorphisms are 
possible causes of bladder cancer (4-6, 9). 
Pathology ofTCC 
The luminal lining of the bladder is composed of a transitional cellular epithelium 
which allows the bladder to distend and accommodate large volumes of urine. Deep to 
this urothelium lies a basal lamina, separating it from the lamina propria. The lamina 
propria contains vessels, lymphatics and nerve fibers. After the lamina propria comes a 
muscularis mucosa, which contains a layer of medium sized vessels. The submucosa 
borders this layer, separating it from the detrusor muscle, a layer consisting of larger 
interlacing bundles of smooth muscle (10). 
Transitional cell carcinomas are staged according to the TNM system (Table 1). 
This system is of limited value in most bladder cancers, because the typical treatment for 
bladder tumors is transurethral resection, and one cannot determine lymph node 




are limited in the diagnosis of pathologic tumor stage. It is possible to determine whether 
invasion into muscle has occurred, but determination of whether the tumor has invaded 
perivesical fat or adjacent organs is not possible. 
Grading of TCC is more subjective than staging, with less reproducible results 
(11). Many grading systems are in use, and two new classification systems, the 
WHO/ISUP 1998 and WHO 1999 systems, have recently been published to avoid 
overdiagnosis of cancer and to create better criteria for the grades (12). These systems 
grade neoplasms based on the degree of order in the architectural pattern and distinction 
of variation of the cellular features building that architecture. According to the WHO 
1999 system, tumors with predominant order in the architectural pattern are considered 
papillary urothelial neoplasms of low malignant potential or grade I tumors, depending 
on the amount of variation in the architecture. Tumors which are predominantly 
disordered are considered high grade carcinomas. These are categorized as grade II 
urothelial carcinomas if focal order is seen within the tissue, and grade III carcinomas if 
no focal order is seen within the tissue (12). 
Natural History of TCC 
Transitional cell carcinoma (TCC) of the urinary bladder may behave in four 
ways if simple resection and fulguration are the sole means of treatment. There may be 
no further recurrence of the tumor, the tumor may recur once or multiple times but 
without change in pathologic stage, the tumor may progress in stage locally within the 
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bladder, or it may spread to distant sites within the body (11, 13). Tumors presenting in 
different stages and with different grades have varied rates of recurrence. 
Most bladder cancers are superficial; that is, tumors not invading muscularis 
propria, stages Tis, Ta, Tla, and Tib. Superficial, well-differentiated papillary TCC 
account for 55-85 percent of tumor presentations (13). Most superficial papillary TCC 
present as solitary tumors, but 30 percent of patients may have multiple tumors (14). 
Heney et al (15) reported on 249 patients in the National Bladder Project 
Collaborative Group A who received only transurethral resection and fulguration of their 
tumors prior to the first recurrence. Four percent of patients who initially presented with 
Ta disease progressed to muscle invasive or metastatic disease, while 30 percent of 
patients with T1 disease progressed. Similarly, 2 percent of grade 1 tumors progressed, 
while 11 percent of grade 2 and 45 percent of grade 3 tumors progressed. Of those 
patients with stage Tl, grade 3 disease, there was a nearly 50 percent risk of progression 
in this study. Progression occurred within two years in most cases. 
In 1986, Fitzpatrick et al (16) reported on a series of patients with Ta, grades 1 
and 2 bladder tumors. They found that after 5 or more years of follow-up, 54 percent had 
developed recurrent tumor. Only 6 percent had a worsened tumor stage. Forty percent of 
those with recurrent tumor had only one recurrence whereas 60 percent of those with 
recurrence had more than one recurrence. Patients in the study who had no evidence of 
tumor recurrence 3 months after initial resection and fulguration had an 80 percent 
chance of remaining tumor-free. Those that did have recurrent tumor at 3 months follow¬ 
up had a high probability of further recurrences. Furthermore, patients with multiple 
. 
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tumors at initial presentation and those with tumors of 10 grams or greater at initial 
presentation tended to have a worse prognosis. 
In a study of 178 patients with stage Ta, grade 1 lesions in the National Bladder 
Project Collaborative Group A who underwent resection and fulguration of bladder 
tumors as the sole means of treatment, Prout Jr. et al. (17) reported recurrences in 61 
percent of patients followed for a median of 58 months. When their tumors recurred, 27 
percent of patients exhibited grade progression while only 4.5 percent showed stage 
progression. 
Recurrence rates and stage progression of stage Ta, grades 1 and 2 tumors are 
important because Ta disease is a relatively benign disease, and patient survival is similar 
to that of age- and sex-matched controls (11). Although the grade and stage of TCC do 
not allow for absolute characterization of whether a tumor will recur and, if it does recur, 
progress to a more invasive tumor, the available evidence overwhelmingly suggests that 
higher grade tumors and increased stage superficial tumors are more likely to be recurrent 
and progressive than lower grade and stage tumors. 
Although carcinoma in situ is classified as a superficial TCC, its natural history is 
quite different than Ta and T1 superficial TCC. Fifty percent of patients with primary 
carcinoma in situ will die of metastatic bladder cancer within two years unless aggressive 
treatment with intravesical therapy, and cystectomy if that fails, is pursued. Because of 
its dismal prognosis and high rates of progression, CIS appears to be a precursor of 
invasive bladder TCC. 
Invasive TCC, stages T2-T4, accounts for 15-20 percent of transitional cell 




percent of these patients (14). Invasive tumors are typically not candidates for 
transurethral resection, and thus cystectomy is the treatment of choice for locally 
advanced disease (18). Fifty percent of those with muscle invasive disease will develop 
metastases (19), and the 5-year survival rate of T2-T3 disease is 20-40 percent (14, 20). 
The behavior of transitional cell carcinoma of the bladder seems such that 
superficial tumors should be resected and treated, recurrences, especially those with 
advanced stage, should be identified promptly, and invasive tumors should be dealt with 
promptly and aggressively. 
Diagnosis 
The primary symptom of eighty percent of patients with TCC of the bladder is 
intermittent hematuria (6, 21, 22). Other common presenting symptoms include irritative 
voiding symptoms such as dysuria, frequency, nocturia and urgency, flank pain, 
abdominal pain and weight loss (22). In the absence of evidence of a medical cause of 
the hematuria such as proteinuria, red blood cell casts or elevated creatinine, patients with 
hematuria are worked-up for urologic causes such as bladder cancer. 
Grossfeld et al (23) reported the American Urological Association Best Practice 
Policy for the evaluation of asymptomatic microscopic hematuria and elucidated 
guidelines for investigating whether those with hematuria without an obvious medical 
cause may be secondary to bladder cancer. Following an in-depth history and physical 
exam, urinalysis and culture is recommended to rule out obvious medical and benign 
causes of hematuria. Next, a complete evaluation includes radiologic imaging of the 
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upper genitourinary tract followed by cystoscopic examination of the bladder in 
appropriate patients. Intravenous urography (IVU) has traditionally been considered the 
best initial radiological study, but computed tomography, magnetic resonance imaging 
and ultrasound are also used by some practitioners. Flexible cystoscopy should be 
performed on all adults older than 40 years and those younger than 40 years with risk 
factors for bladder cancer. In addition to cystoscopy in some patients, and in all patients 
who do not receive cystoscopy, urinary cytology should be performed as a highly specific 
screening tool for bladder cancer. If bladder cancer is suspected from these tests, 
confirmation should be made with appropriate radiological measures and/or rigid 
cystoscopy, and treatment decisions should be made following accurate staging of the 
tumor. 
New Methods ofTCC Detection 
While the combination of cystoscopy and cytology remains the gold standard for 
evaluation of TCC, intense research is underway to develop new tests that may prove 
more useful. The ideal test would be a simple, inexpensive, noninvasive point of use test 
with high sensitivity and specificity for new and recurrent bladder cancer. Although 
early detection of all bladder tumors would theoretically be the goal of such a test, the 
low prevalence of bladder cancer in the general population and the low proportion of high 
grade and invasive tumors makes general population screening impractical due to cost 
and the number of false-positive results that would ensue (24). Thus, a more practical 
* 
9 
use of such tests would be to investigate hematuria, screen high risk individuals, and 
screen patients for recurrence of bladder tumors. 
Monitoring tumor recurrence would be an important function of any useful 
bladder tumor marker. Earlier diagnosis of a cancer is thought to improve outcome 
inasmuch as treating a smaller cancer should lead to improved cure rates (25). Since 
greater than 50 percent of those presenting initially with superficial tumors will develop 
recurrent tumors (16), and recurrence is often accompanied by progression to a more 
invasive tumor, patients are currently followed by cystoscopy every 3 to 6 months for at 
least one year, and yearly thereafter, in an attempt to detect recurrence while it is still 
treatable. This method of surveillance is expensive, uncomfortable for the patient, has a 
risk of morbidity, and may not detect flat lesions. A urinary tumor marker test, if proven 
to be as sensitive and specific as cystoscopy and cytology, could improve patients’ 
experience and outcome by offering an affordable, non-invasive (and therefore 
morbidity-free), accurate test that would predict or at least identify tumor recurrence. 
Many such tests are currently available or under development (table 2), but none 
of them have yet proven to be a replacement for cystoscopy or cytology. Like cytology, 
most of these assays are highly specific to TCC of the bladder. The results of the many 
studies on these markers show that nearly all of the currently available assays have a 
comparable or higher sensitivity than cytology, but a lower specificity (26), and thus are 
not suitable replacements at this time. The methods that are not currently commercially 
available, including telomerase, BLCA-4, hyaluronic acid/hyaluronidase and survivin are 




Apoptosis, or programmed cell death, is governed by networks of pathways which 
induce or prevent cell death in order to achieve tissue homeostasis. This cell death is 
mediated by intracellular proteases called caspases, and results in membrane-encased 
fragments of cells which are cleared by phagocytosis. Dysregulation of processes 
controlling apoptosis is thought to contribute to neoplastic cell expansion and 
carcinogenesis (27). 
One family of apoptosis regulators, the Bcl-2 family, is comprised of apoptosis¬ 
suppressing and apoptosis inducing members. Alterations in their expression due to 
structural changes in the genes or changes in transcriptional and post-transcriptional 
regulatory networks may cause imbalances in the ratio of anti-apoptotic to pro-apoptotic 
proteins, leading to cells that are resistant to death stimuli (27). 
Another family, the inhibitors of apoptosis protein (IAP) family, was first 
described in bacloviruses in 1993 (28). This widely expressed family is thought to 
suppress apoptosis through direct caspases and pro-caspase inhibition, primarily caspases 
3 and 7, and interaction with NF-kB (29). IAPs are thought to contribute to oncogenesis 
and tumor progression, and the strongest evidence to support this notion is found in data 
that have accumulated about the IAP survivin (29). 
Survivin, a member of the IAP family first described in 1997 by Ambrosini et al 
(30), is a unique member of the IAP family which contains a single baculovirus IAP 
repeat and lacks a carboxyl-terminal RING finger, which is found in certain IAPs (31, 
32). In their initial paper, Ambrosini et al noted expression of survivin in fetal tissues. 
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lung, colon, pancreas, prostate and breast cancers, and high-grade non-Hodgkin’s 
lymphomas, but not terminally differentiated adult tissues nor low-grade lymphomas 
(30). Since that time, it has also been found to be over-expressed in neuroblastoma (33), 
leukemia (34), pheochromocytoma (35), glioma (36), melanoma (37), and gastric (38), 
esophageal (39), hepatic (40), uterine (41), ovarian (42), and bladder (43) cancers. 
Furthermore, studies have found that survivin is expressed in select non-cancerous 
tissues, including prostatic neuroendocrine cells (44), proliferating endometrium (45), 
and quiescent CD34+ bone-marrow-derived stem cells (46). 
Survivin and Bladder Cancer 
Because survivin is overexpressed in many tumors but not in most normal tissues, 
Swana et al (43) investigated whether it was expressed in bladder tumor tissue. To that 
end, they immunohistochemically studied the primary tumors of 36 patients with 
localized bladder cancer for expression of survivin, bcl-2, and p53. The subjects included 
25 men and 11 women with a mean age of 66 years. Survivin was detected in 28 of the 
36 tumors studied, including 65 percent of grade 1 tumors, 90 percent of grade 2 tumors, 
and 100 percent of grade 3 tumors. Survivin was not detected in normal bladder 
urothelium. Furthermore, patients with grade 1 tumors staining survivin-positive 
recurred more quickly (12±6 months) than patients whose grade 1 tumors did not stain 





Since survivin was detected in bladder tumor tissue and not normal bladder 
urothelium. Smith et al (47) performed preliminary studies to determine whether survivin 
could be detected in the urine of patients with bladder cancer. Urine specimens were 
collected from healthy volunteers (n=17), patients with nonneoplastic urinary tract 
disease (n=30), genitourinary cancer other than TCC(n=30), new-onset or recurrent 
bladder cancer (n=46), and successfully treated bladder cancer, as determined by negative 
post-treatment cystoscopy (n=35). Samples were analyzed using an antibody-based, dot- 
blot assay. Western Blot and reverse transcriptase polymerase chain reaction. Sensitivity 
for new-onset and recurrent bladder cancer was 100 percent, and specificity for other 
neoplastic and nonneoplastic genitourinary tract diseases was 95 percent. This high 
sensitivity and specificity test showed promise in this study as a potential tumor assay for 
both new and recurrent bladder cancer. 
Urinary testing for survivin appears to be a promising method of surveillance for 
bladder cancer. Because recurrent cancer, especially recurrent TCC which has increased 
in grade or become more invasive, is a major problem facing urologists and bladder 
cancer patients, and because the current methods of surveillance have significant 
drawbacks and limitations, we hypothesize that urinary survivin measured by the Bio-dot 
antibody based assay is a highly sensitive and specific marker for high grade, invasive 




Statement of Purpose and Hypothesis 
Urinary testing for survivin appears to be a promising method of surveillance for 
bladder cancer. Because recurrent cancer, especially recurrent TCC which has increased 
in grade or become more invasive, is a major problem facing urologists and bladder 
cancer patients, and because the current methods of surveillance have significant 
drawbacks and limitations, we hypothesize that urinary survivin measured by the Bio-dot 
antibody based assay is a highly sensitive and specific marker for high grade, invasive 
TCC of the bladder. We hope that this technique will prove to be an effective method for 





121 clean-catch or straight catheter urine samples were collected at the urology 
clinics at Yale-New Haven Hospital and the Veterans Affairs, New England Health Care 
Systems, West Haven, Connecticut, Division. These samples were taken from patients 
with a pathologically documented history of bladder cancer which was treated at least 
two months prior to sampling. The nursing staff and house officers at these institutions 
obtained the samples. Urine samples were aliquoted and stored in aliquots at -80°C until 
analysis. 
Urine detection ofsurvivin 
The protocol is as previously published (47) except for the use of longer 
incubation times with the primary antibody, a secondary antibody to a fragment of IgG 
which was more sensitive and specific than the antibody to holo-IgG, longer times for 
detection of the chemilluminescent product, and the use of frozen whole urine samples. 
Frozen whole urine samples frequently contain more survivin than urine samples that are 
centrifuged and the supernatants subsequently frozen. On the day of survivin analysis, 
urine samples were thawed and centrifuged at 20,000 x g for 20 minutes. Meanwhile, the 
Bio-Dot Microfiltration Apparatus was assembled with a 0.2 [X nitrocellulose membrane 
(Bio-Rad Laboratories, Hercules, CA) that had been moistened in 20 mM Tris-buffered 
saline (pH 7.5). Then, the urine supernatants (500 p\), along with increasing 
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concentrations (0.1-100 ng/ml) of E.coli-expressed recombinant survivin as a standard 
(48), survivin-negative protein controls and survivin-positive and negative control urine 
samples were filtered onto the membrane. 
After filtration, the membrane was incubated (2 hours, 4°C) with 5% nonfat dry 
milk and 0.01% sodium azide in PBS, pH 7.4. After washing in PBS-Tween 20 (0.5%), 
the membrane was incubated overnight at 4°C, with 2 jUg/ml of a rabbit polyclonal 
antibody to survivin (37), washed with PBS-Tween (0.05%), and incubated with a 
1:24,000 dilution of a horseradish peroxidase-conjugated donkey anti-rabbit F(ab')2 
fragment of IgG (Jackson ImmunoResearch, West Grove PA) (1 hour, 22C). After two 
washes each in PBS, PBS-Tween (0.05%) and PBS again, binding of the primary 
antibody was detected by enhanced chemilluminescence (Amersham Biotech, Piscataway 
NJ). Blots were scanned and concentrations of survivin were determined using the 
Kodak Digital Science ID Image Analysis System (Eastman Kodak Co., Rochester, NY). 
This was followed by determination of a survivin value for each sample based on the 
antibody reactivity relative to six survivin standards (0.1-100 mg/ml). 
Urine sample database 
The urine samples were collected between 2000-2001, and were analyzed by the 
laboratory in a blind manner. Because of this, the diagnosis of each patient at the time 
urine samples were obtained was unknown. Unfortunately, since bladder cancer is a 
complex disease with multiple methods of diagnosis and a tendency to recur months to 
years post-treatment, the classification of patients’ diagnosis for each urine sample could 
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not be completely described with a simple evaluation of pathology reports. We therefore 
decided to create a database of the entire urological medical record for each patient 
enrolled in the study. 
We specifically constructed a database to be used to categorize all patients with 
hematuria, new-onset bladder cancer, bladder cancer in remission, and recurrent TCC 
using FileMaker Pro 5.0 (FileMaker, Inc., Santa Clara, CA). We designed this database 
to contain all of the information required to accurately assess the bladder cancer status of 
each patient at any given time, including cystoscopy, cytology, and therapeutic 
information. In addition, we included demographic data, information about the patient’s 
prostate and renal status, results of all imaging studies performed on the patient, and any 
other information which might contribute to the patient’s medical status. This 
information should also make the database quite useful in other studies involving 
urologic patients at our institutions. 
Since the database was to contain such a large volume of data (much of the above 
mentioned data were repeated multiple times for each patient, and all such studies in each 
patient’s medical record were included in the database), we used forms to create the 
appearance of multiple pages for each record, all linked by a background of the patient’s 
demographic data (Figures 1 and 2). Tabs were created to easily switch between forms, 
and navigation buttons were included at the top of the database to allow for quick 
navigation between records. 
Once the database was created, we surveyed the medical records of all patients 
from whom urine samples were obtained and entered all of the appropriate data into the 
database. Efforts were made to ensure that the medical record was complete for each 
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patient, and only diagnoses of recurrent cancer which were verified by pathological data 
from cystoscopy biopsy specimens were included in the study. Samples from patients in 
remission without recurrence within one year after the sample was given were included in 
the remission group, and patients with cystoscopic biopsies with pathology positive for 
TCC at the time of urine sample were included in the recurrence group. All patients 
included in the study had at least one year of follow-up. 
Data analysis and statistics. Assignment of recurrence and remission status is 
determined by post treatment cystoscopy (± biopsy). Differences between groups were 
determined using Statview (SAS Institute, Cary, NC). Study results were expressed as 
the mean ± standard error, and as the median. Outcome of treatment was analyzed using 
non-parametric analysis including the signed t test and Mann-Whitney U tests. The 
detection limit of the assay is 0.03 ng/ml survivin with no nonspecific background, and 
all values below this level were treated as 0. 
Exclusionary criteria 
All patients from whom urine samples had been reserved were initially eligible 
for inclusion in this study. Those patients with recurrent bladder cancer and/or bladder 
cancer in remission were selected from the database for this analysis. Samples from 
patients undergoing intravesical chemotherapy or immunotherapy were excluded due to 
possible confounding effects of this therapy on survivin levels (Hausladen et al, in press). 
Patients who had visual recurrence of tumor without biopsy-proven pathological data to 
. 
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document TCC were excluded because some patients with visual tumor recurrence had 
negative pathology specimens. All patients with biopsies negative for TCC were 
included in the remission group. Patients who were in remission at the time that the 
sample was gathered but developed recurrent TCC during the follow-up period were 
excluded in the study. 
The author performed two of the Bio-Dot assays. Marcia A. Wheeler did the 
remainder of the assays and all of the digital survivin quantification. J.J.C., C.J.C., and 
D.A.H. were primarily involved in the pre-design planning of the database. J.J.C. 
implemented the database, and J.J.C., C.J.C., and D.A.H. acquired data. J.J.C. performed 




Determination of urine survivin with the Bio-Dot apparatus was performed on 
121 samples. Eighty-nine of these samples were taken from men in remission from TCC 
and nine from women in remission All of the patients in remission were free of tumor for 
at least one year after the sample was obtained. Twenty samples represented men with 
recurrent TCC, and three samples were taken from women with recurrent cancer. The 
mean age (±SD) of patients in the remission group was 68.2 (±12.4) years and the mean 
age of those patients with tumor was 72.0 (±10.9) years (Table 4). Of those with 
recurrent TCC, 16 males and one female had superficial recurrent disease while four 
males and two females have invasive recurrent disease. Eleven men and one woman had 
low-grade recurrence, while nine men and two women had high-grade recurrence (Table 
5). 
Survivin was detected in 34 of the 98 (34.7%) samples from patients with TCC in 
remission and 12 of the 23 (52.2%) samples from patients with recurrent disease (Table 
3). It was detected in 7 of the 17 (41.2%) cases of superficial recurrence and 5 of the six 
(83.3%) cases of invasive recurrence, and 6 of 12 (50%) cases of low-grade recurrence 
and 6 of 11 (54.5%) cases of high-grade recurrence (Table 3). 
When normalized for a weighted mean (SD) survivin level, patients with recurrent 
TCC had significantly higher survivin levels than patients in remission [0.54 
ng/mL(±1.17) vs. 0.07 ng/mL (±0.15), p<0.001] (Table 4). 
The correlation between survivin score and histopathologic grading and staging is 
shown in Table 4 and graphically depicted in Figures 3 and 4. Survivin values for high 
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grade recurrent tumors were significantly higher than survivin values for patients in 
remission [0.75 ng/mL (±1.49) vs 0.07 ng/mL (±0.15), p=0.029], but there were no 
statistically significant differences between the survivin levels of low grade recurrent 
tumors vs. remission and the survivin levels of high grade recurrent tumors vs. low grade 
recurrences. Survivin values for invasive recurrent tumors were significantly higher than 
survivin values of patients in remission [1.35 ng/mL (±1.86) vs. 0.07 ng/mL (±0.15), 
p<0.001] and survivin values of patients with superficial recurrence [1.35 ng/mL (±1.86) 
vs. 0.25 ng/mL (±0.67), p=0.012]. 
Using a threshold value of 0.12 ng/mL survivin, this test is 84.7% specific for 
TCC in remission. The overall sensitivity of this assay for recurrent TCC of the bladder 
is 52.2% (Table 6). The sensitivities for low grade recurrence and high grade recurrence 
are 50.0% and 54.5%, respectively. The sensitivities for superficial recurrence and 





In this study, we investigated whether an antibody-based urinary assay for the 
inhibitor of apoptosis survivin could be used to differentiate whether patients with 
previously treated bladder cancer remained in remission or had recurrent bladder tumors. 
We found that patients with recurrent TCC of the bladder had significantly higher urinary 
levels of survivin than patients with TCC in remission. This effect is most pronounced 
when comparing the levels in patients with invasive recurrence and high grade recurrence 
to those patients in remission. 
Survivin was detected in 34 of the 98 (34.7%) samples from patients with TCC in 
remission and in 12 of the 23 (52.2%) samples from patients with recurrent disease 
(Table 3). It was detected in 7 of the 17 (41.2%) cases of superficial recurrence and 5 of 
the six (83.3%) cases of invasive recurrence, and 6 of 12 (50%) cases of low-grade 
recurrence and 6 of 11 (54.5%) cases of high-grade recurrence. 
The overall sensitivity of the assay for recurrent bladder cancer in this series is 
52.2% at a cutoff survivin value of 0.12 ng/mL, and the specificity is 84.7% at this 
threshold. The sensitivity ranges from 41.2% for identifying superficial recurrence to 
83.3% for identifying invasive recurrence. 
Previous pathologic studies of survivin (43) had shown that survivin was detected 
in 28 of the 36 tumors studied, including 65 percent of grade 1 tumors, 90 percent of 
grade 2 tumors, and 100 percent of grade 3 tumors, and was not detected in normal 
bladder epithelium. Our data agree with those of Swana et al, in that urinary survivin 




and a higher proportion of urines were positive for survivin in more aggressive (higher 
grade and invasive) tumors. Although Swana et al did not detect survivin in normal 
bladder urothelium, 34.7% of patients in remission in our series had detectable urinary 
levels of survivin. Although these patients were free of recurrence for one year after we 
collected their samples, it is possible that these patients will be more likely to be in the 
cohort of greater than 60% of bladder cancer patients who develop recurrent tumor. 
Also, the normal epithelium that Swana et al studied had not had prior episodes of TCC. 
Smith et al (47) found this Bio-dot assay to be 100 percent sensitive for new-onset 
and recurrent bladder cancer, and 95% specific for other neoplastic and nonneoplastic 
genitourinary disease. Our specificity of 84.7% is nearly the level that Smith et al found, 
which compares favorably to existing tests and is more impressive since our controls 
were all patients who had previously been treated for TCC, while other methods of 
detecting bladder cancer have traditionally been tested comparing samples from cancer 
patients with samples from patients without a history of TCC. The sensitivities obtained 
in our study were considerably lower than reported in that previous study, with the 
exception of invasive recurrent TCC. This was not entirely unexpected, however. 
Histopathologic analysis of bladder epithelium by Swana et al only found survivin in 
65% of epithelium with grade 1 lesions. Further, the collection of urine samples in this 
study was not ideally standardized. We did not determine the amount of time that urine 
basted in each patient’s bladder before collection. It seems reasonable to assume that 
urine with more contact time with urothelium containing a bladder tumor would have a 
higher likelihood of staining for survivin in the dot-blot assay. To decrease this 
„ 
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confounding factor, urine samples in future studies would ideally be collected by patients 
as a first morning void on the date of their clinic appointment. 
The retrospective design of our database and method of sample collection 
unfortunately did not allow us to determine whether urinary survivin could predict 
recurrence of TCC. Although we analyzed the urine of patients in remission, only five of 
those patients progressed to having recurrent tumors after the date we collected the urine. 
Additionally, we did not aliquot urine samples for those patients when they did recur, 
making comparison of survivin levels impossible. A design change in future studies 
would correct this and allow us to determine the predictive accuracy of survivin for 
recurrence. If we analyzed urine samples at every visit of all bladder tumor patients seen 
in the clinics, we would be able to better determine whether urinary survivin could 
predict as well as identify TCC. 
Although cystoscopy in conjunction with cytology is the gold standard for bladder 
tumor follow-up, less than half of the survivin samples which we included in our study 
had cytology results in addition to cystoscopy results. Because of this, we were unable to 
compare our method for identifying bladder tumor recurrence with cytology. Future ' 
studies should assure that urine samples are sent for cytologic analysis in addition to 
survivin. Also, since we did not have cytology data for all of the patients, and 
cystoscopic biopsies were only commonly obtained on patients with visual lesions, it is 
possible that some patients whom we included in the remission group actually had 
recurrent TCC at the time the urine sample was taken. This would cause the calculated 




Finally, the large number of subgroups in our study and relative frequencies of 
different grades and stages of TCC caused the number of patients in some of our groups 
to be low; for instance, there were only 6 patients in this study with recurrent, invasive 
tumors. A larger study in the future may allow us to break these groups down even 
further and detect finer variations in the level of survivin. 
The search for a highly sensitive and specific, easily accessible marker for bladder 
cancer remains an elusive tool in the treatment of TCC. Many such tests are currently 
available or under development, but none of them have yet proven to be a replacement 
for cystoscopy or cytology. The inhibitor of apoptosis survivin is overexpressed in many 
human cancers including TCC of the bladder, and may prove to be a useful molecular 
marker in diagnosing and predicting recurrence of TCC. We showed that urinary 
survivin values are significantly higher for patients with recurrent TCC than patients with 
TCC in remission. This test is highly sensitive for cancer in remission, and is highly 
specific for invasive recurrent tumors. Future studies may be able to determine whether 
urinary survivin could be used as a tool to predict TCC recurrence in place of or in 
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Table 1. TNM Staging of Bladder Carcinoma 
Primary Tumor (T) 
Tx Primary tumor cannot be assessed 
TO No evidence of primary tumor 
Ta Non-invasive papillary carcinoma 
Tis Carcinoma in situ 
T1 Tumor invades sub-epithelial connective tissue 
Tla Basement membrane penetration 
Tib Lamina propria invasion 
T2 Tumor invades the detrusor muscle 
T2a Superficial (inner half) muscle invasion 
T2b Deep (outer half) muscle invasion 
T3 Tumor invades the perivesical tissue 
T3a Microscopic invasion 
T3b Macroscopic invasion 
T4 Tumor invades any of the following: 
T4a Prostate, uterus, vagina 
T4b Pelvic wall, abdominal wall 
Regional Lymph Nodes (N) 
Nx Regional lymph nodes not assessed 
NO No regional lymph node metastases 
N1 Single nodal metastases (<2 cm) 
N2 Single or multiple nodal metastases (none >2-5 cm) 
N3 Nodal metastases (>5cm) 
Distant Metastases (M) 
Mx Distant metastases not assessed 
MO No distant metastases 
Ml Distant metastases 










































































































































CL -Q 0 

















T— o CO o Q 
CO CD op 
uS h- |V. 



































o CM CO 
CD 00 op 
CO o to 














0 ° 0 0 0 0 r— JL2 
L_ i_ c c c C 
~ 03 L. ■»_ 











































































0 0 o o 0 CL 0 p 
X X CO 4“ o 
z 



















































































































































































































































TD ■O T3 T3 ~o 
CD >, CD >, CD >, 0 >, 0 >, 
N br N ir N ir N hr N hr 
— o = O := o := O = O 
.2 0 .2 03 .2 to .2 to .2 to 
O i- O ir O hr o »- O hr 
CD O 0 O 0 O 0 O 0 O 
CL -Q CL -O CL -O CL -O CL -Q 




























0 0 =3 
C 












c o c 
0 _Q 0 
E i -t—* E 









■E o _0 £ s 4— 
L. 0 X "0 ±- 0 
X CD 0 O X £) 
< 
Z 0 


















































































o 0 N c 
c £ 0 ID < 
0 













Table 3. Numbers of samples which had detectable survivin for 










Remission (n=98) 34 64 34.7 
All Recurrent Tumors (n=23) 12 11 52.2 
Low Grade Recurrence (n=12) 6 6 50.0 
High Grade Recurrence (n=11) 6 5 54.5 
Superficial Recurrence (n=17) 7 10 41.2 
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Table 6. Sensitivity and Specificity of Urinary Survivin for Recurrent Tumors 
Survivin Cutoff %Sensitivity %Specificity 
Recurrent Tumor 0.119 52.2 84.7 
Low Grade Recurrence 0.119 50 84.7 
High Grade Recurrence 0.119 54.5 84.7 
Superficial Recurrence 0.119 41.2 84.7 
Invasive Recurrence 0.119 83.3 84.7 
. 
Figure 1. 
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Figure 1. A Representative Entry for Bladder Biopsy Pathology Findings. 
Demographic information about a test subject appears at the top of all 
forms within each subject’s entry. Tabs, labeled “Urine Cytology,” “Bladder 
Path,” “Cystoscopy,” “Prostate,” “Kidney,” “Imaging,” “BCG,” and “Other” 
direct the user to the form containing information relevant to each title. 
This form, which has data regarding a patient’s bladder pathology 
specimens, tells the researcher whether each dated sample contained TCC, 
the depth of invasion of that cancer, its grade, how the sample was 




Q File Edit View Insert Format Records Scripts Window Help 
d is m v i ^ n®© s: ^ 13 
B F '' If 
i Unsoited 
Last Name Subject 
Fist Name [Test 
timniinimiiiimciniHiniiiiiiiiiK 





Pack Years ;70 
Recert Tobacco No 
Cystoscopy 
Dale Fixings 




! visual recurrence 
14/28/1999 
7/28/1999 
i trabeculatioris, visual tumor recurrence 
I no lesion 
19/29/1999 j Ino lesion 
1/5/2000 l [visual recurrence 
•3/22/2000 j [visual recurrence 
jC 
][ 
Figure 2. A Representative Entry for Visual Cystoscopic Findings. As in 
the previous figure, demographic information is at the top of the screen, 
and tabs allow movement between forms within subject’s entry. This form 
contains dated data for all of the visual cystoscopic findings in this 
patient’s medical record. 

Figure 3. 
Figure 3. A box and whiskers plot depicting the survivin levels of 
patients in remission, patients with low grade recurrence and patients 
with high grade recurrence. Survivin values for high grade recurrent 
tumors were significantly higher than survivin values for patients in 
remission *[0.75 ng/mL (±1.49) vs 0.07 ng/mL (±0.15), p=0.029], but there 
were no statistically significant differences between the survivin levels 
of low grade recurrent tumors vs. remission and the survivin levels of 
high grade recurrent tumors vs. low grade recurrences. 

Figure 4. 
Figure 4. A box and whiskers plot depicting the survivin levels of 
patients in remission, patients with superficial recurrence and patients 
with muscle invasive recurrence. Survivin values for invasive recurrent 
tumors were significantly higher than survivin values of patients in 
remission **[1.35 ng/mL (±1.86) vs. 0.07 ng/mL (±0.15), p<0.001] and 
survivin values of patients with superficial recurrence ***[1.35 ng/mL 
(±1.86) vs. 0.25 ng/mL (±0.67), p=0.012]. The difference in survivin values 
between patients with superficial recurrence and patients in remission 





HARVEY CUSHING/JOHN HAY WHITNEY 
MEDICAL LIBRARY 
MANUSCRIPT THESES 
Unpublished theses submitted for the Master’s and Doctor’s 
degrees and deposited in the Medical Library are to be used only with 
due regard to the rights of the authors. Bibliographical references 
may be noted, but passages must not be copied without permission of 
the authors, and without proper credit being given in subsequent 
written or published work. 
This thesis by 
has been used by the following person, whose signatures attest their 
acceptance of the above restrictions. 
NAME AND ADDRESS DATE 
YALE MEDICAL LIBRARY 
3 9002 0 061 61 35 

